|Drug Patent Number||Company||Drug Patent Title||Drug Patent Expiry||Activity Alert|
|These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.|
|US8080580||MERCK SHARP DOHME||Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives|| |
(6 years from now)
Steglatro is owned by Merck Sharp Dohme.
Steglatro contains Ertugliflozin.
Steglatro has a total of 1 drug patent out of which 0 drug patents have expired.
Steglatro was authorised for market use on 19 December, 2017.
Steglatro is available in tablet;oral dosage forms.
Steglatro can be used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.
The generics of Steglatro are possible to be released after 13 July, 2030.
|Drug Exclusivity||Drug Exclusivity Expiration|
|M (M)||Sep 17, 2024|
Market Authorisation Date: 19 December, 2017
Treatment: An adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic